Azitra Files S-1 for Resale of Up to 51.7M Shares, Eyes $18M from Warrants

TL;DR

**Azitra's S-1 signals significant dilution risk from selling stockholders, but potential warrant exercises offer a much-needed cash infusion for its pipeline.**

AI Summary

Azitra, Inc. (AZTR) is an early-stage clinical biopharmaceutical company focused on precision dermatology, utilizing engineered proteins and topical live biotherapeutic products. The company has a proprietary microbial library of approximately 1,500 unique bacterial strains and leverages AI/machine learning for drug discovery. Azitra is not selling any securities in this S-1 filing and will not receive proceeds from the sale of shares by Selling Stockholders, but may receive up to approximately $1.57 million from the exercise of November Warrants and November Placement Agent Warrants. Additionally, Azitra may receive up to approximately $14.0 million from the sale of ELOC Shares to Alumni Capital LP, in addition to the approximately $6.0 million already received, and up to approximately $2.5 million from the exercise of ELOC Warrants. The company's common stock is listed on the NYSE American under the symbol "AZTR," with a last reported sale price of $0.3654 per share on December 9, 2025. A one-for-6.66 reverse stock split took effect on August 21, 2025. Key programs include ATR-12 for Netherton syndrome (Phase 1b, topline data expected Q1 2026), ATR-04 for EGFRi-induced rash (Phase 1/2, first patient dosed Q3 2025), and ATR-01 for ichthyosis vulgaris (IND filing in 2026).

Why It Matters

This S-1 filing is crucial for investors as it details the potential dilution from the resale of up to 51,716,696 shares by Selling Stockholders, including Alumni Capital LP. While Azitra will not receive direct proceeds from these resales, the potential exercise of warrants could inject up to $18.07 million into the company, providing capital for its early-stage clinical programs like ATR-12 and ATR-04. The significant number of shares being registered for resale, coupled with the recent 1-for-6.66 reverse stock split on August 21, 2025, highlights potential downward pressure on the stock price, which closed at $0.3654 on December 9, 2025. This capital is vital for Azitra to compete in the precision dermatology space against larger pharmaceutical companies.

Risk Assessment

Risk Level: high — The risk level is high due to the substantial potential for dilution from the resale of up to 51,716,696 shares by Selling Stockholders, which includes 38,408,903 ELOC Shares and 4,687,500 November Common Stock Purchase Warrant Shares. The company's stock price was $0.3654 on December 9, 2025, indicating a low valuation for an early-stage biopharmaceutical company, and the recent 1-for-6.66 reverse stock split on August 21, 2025, often precedes further price declines.

Analyst Insight

Investors should exercise extreme caution due to the significant potential for dilution from the registered resale shares. Monitor the volume and pricing of these resales closely, as they could exert downward pressure on AZTR's stock. Consider the potential cash infusion of up to $18.07 million from warrant exercises as a positive, but weigh it against the dilution risk and the early-stage nature of Azitra's clinical pipeline.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• 38,944,662 — Shares of Common Stock (Maximum shares registered for resale by Selling Stockholders)
• 4,151,741 — Shares of Common Stock (Underlying the November Pre-Funded Warrants)
• 4,687,500 — Shares of Common Stock (Underlying the November Common Stock Purchase Warrants)
• 187,500 — Shares of Common Stock (Underlying the Placement Agent Warrants)
• 3,840,890 — Shares of Common Stock (Underlying the ELOC Warrants)
• $1.57 million — Aggregate gross proceeds (Expected from cash exercise of November Warrants and November Placement Agent Warrants)
• $14.0 million — Aggregate gross proceeds (Expected from sale of ELOC Shares to Alumni Capital LP (in addition to $6.0 million already received))
• $2.5 million — Aggregate gross proceeds (Expected from cash exercise of currently issued and future ELOC Warrants)
• $0.3654 — Last reported sale price per share (On NYSE American on December 9, 2025)
• 1:6.66 — Reverse Stock Split ratio (Took effect on August 21, 2025)

Key Players & Entities

• Azitra, Inc. (company) — Registrant in S-1 filing
• Alumni Capital LP (company) — Selling Stockholder and counterparty in ELOC Purchase Agreement
• Francisco D. Salva (person) — Agent for service for Azitra, Inc.
• Thompson Hine LLP (company) — Legal counsel for Azitra, Inc.
• Faith L. Charles, Esq. (person) — Legal counsel from Thompson Hine LLP
• Todd Mason, Esq. (person) — Legal counsel from Thompson Hine LLP
• NYSE American (regulator) — Stock exchange where AZTR is listed
• United States Food and Drug Administration (regulator) — Regulatory body for drug approvals
• Carnegie Mellon University (company) — Academic partner for research collaboration
• Fred Hutchinson Cancer Center (company) — Academic partner and licensor of SyMPL technologies

FAQ

Risk Factors

• Alumni Capital Transactions Uncertainty [medium — financial]: The company may receive up to $14.0 million from the sale of ELOC Shares to Alumni Capital LP, in addition to $6.0 million already received, and up to $2.5 million from ELOC Warrants. The completion and timing of these transactions are subject to various conditions and could impact the company's cash position and funding runway.
• Warrant Exercise Proceeds Uncertainty [low — financial]: Azitra may receive up to approximately $1.57 million from the exercise of November Warrants and November Placement Agent Warrants. The actual proceeds depend on the exercise decisions of warrant holders and the timing of such exercises.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: Azitra's lead programs, ATR-12 (Netherton syndrome) and ATR-04 (EGFRi-induced rash), are in early-stage clinical trials. Topline data for ATR-12 is expected in Q1 2026, and ATR-01 requires an IND filing in 2026. Delays or adverse results in these trials could significantly impact development timelines and future regulatory approvals.
• Early-Stage Commercialization and Market Adoption [medium — market]: As an early-stage company focused on precision dermatology, Azitra faces the inherent risks of developing novel therapies. Market adoption of its proprietary microbial library and AI/ML-driven drug discovery approach is unproven, and competition in the dermatology space is significant.
• Reverse Stock Split Impact [low — financial]: A 1-for-6.66 reverse stock split took effect on August 21, 2025. While intended to increase the stock price, reverse splits can sometimes be perceived negatively by investors and may not guarantee sustained price improvement.

Industry Context

Azitra operates in the precision dermatology and biopharmaceutical sector, focusing on novel topical therapies. The industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Key trends include the increasing use of AI/ML in drug discovery and a growing demand for targeted therapies for rare and chronic skin conditions.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Azitra is subject to stringent regulatory oversight from bodies like the FDA. Successful development and approval of its product candidates depend on demonstrating safety and efficacy through rigorous clinical trials. Any delays or adverse findings in these trials could have significant financial and strategic implications.

What Investors Should Do

1. Monitor clinical trial progress and data releases.
2. Evaluate the impact of the Alumni Capital transactions.
3. Assess competitive landscape in precision dermatology.
4. Consider the implications of the reverse stock split.

Key Dates

• 2025-08-21: Reverse Stock Split — A 1-for-6.66 reverse stock split was implemented, impacting the number of outstanding shares and per-share metrics.
• 2025-Q3: First Patient Dosed in ATR-04 Trial — Marks the commencement of clinical evaluation for ATR-04, a key program for EGFRi-induced rash.
• 2026-Q1: Topline Data Expected for ATR-12 — Anticipated release of key clinical data for ATR-12, a potential treatment for Netherton syndrome, crucial for future development decisions.
• 2026: IND Filing for ATR-01 — Planned submission of an Investigational New Drug application for ATR-01, paving the way for clinical testing in ichthyosis vulgaris.

Glossary

Live Biotherapeutic Products (LBPs)

Therapeutic products consisting of or derived from live microorganisms, such as bacteria, intended to treat or prevent disease. (Azitra's core technology platform involves developing LBPs for dermatological conditions.)

Proprietary Microbial Library

A collection of unique microorganisms owned and controlled by the company, used as a source for drug discovery. (Azitra possesses a library of approximately 1,500 unique bacterial strains, forming the basis of its product pipeline.)

AI/Machine Learning

Artificial intelligence and machine learning techniques used to analyze data, identify patterns, and accelerate drug discovery processes. (Azitra leverages these technologies to enhance its drug discovery and development efforts.)

Netherton Syndrome

A rare genetic disorder characterized by severe skin inflammation, hair abnormalities, and increased susceptibility to infections. (Azitra's lead candidate, ATR-12, is being developed for this indication.)

EGFR Inhibitor-Induced Rash

A common side effect of certain cancer therapies (EGFR inhibitors) that causes skin rashes. (Azitra's candidate ATR-04 is being investigated for the treatment of this condition.)

Ichthyosis Vulgaris

A common, inherited skin disorder characterized by dry, scaly skin. (Azitra's candidate ATR-01 is intended for the treatment of this condition.)

IND Filing

Investigational New Drug application, a submission to regulatory authorities (like the FDA) to seek permission to start clinical trials in humans. (Azitra plans to file an IND for ATR-01 in 2026.)

Reverse Stock Split

A corporate action where a company reduces the number of its outstanding shares by consolidating them, typically to increase the per-share market price. (Azitra implemented a 1-for-6.66 reverse stock split in August 2025.)

Year-Over-Year Comparison

This S-1 filing represents a significant update from previous disclosures, particularly regarding the company's clinical development pipeline and financing activities. Key programs like ATR-12 and ATR-04 have advanced into clinical trials, with specific data release timelines now provided. Furthermore, the filing details substantial potential financing through transactions with Alumni Capital LP and warrant exercises, which are critical for future operations. The reverse stock split is a new development impacting share structure. Specific financial metrics like revenue, net income, and margins are not detailed in this S-1, which focuses on registration of securities and forward-looking development plans.

Key Financial Figures

• $0.0001 — ”) of our common stock, par value $0.0001 per share (the “Common Stock&rdqu
• $1.57 million — e gross proceeds of up to approximately $1.57 million. The ELOC Shares and the ELOC Warrant
• $14.0 million — e gross proceeds of up to approximately $14.0 million from the sale of the ELOC Shares to the
• $6.0 million — ement (in addition to the approximately $6.0 million previously received from sales made pur
• $2.5 million — is prospectus), and up to approximately $2.5 million upon exercise for cash of the currently
• $0.3654 — NYSE American on December 9, 2025, was $0.3654 per share. You should read this prospe
• $6.3 billion — s sold to AstraZeneca for approximately $6.3 billion in a staged acquisition in 2016. He als
• $21.0 billion — uently sold to Abbvie for approximately $21.0 billion in 2015. Before that, Mr. Salva spent a

Filing Documents

• forms-1.htm (S-1) — 533KB
• ex5-1.htm (EX-5.1) — 19KB
• ex23-2.htm (EX-23.2) — 1KB
• ex107.htm (EX-FILING FEES) — 41KB
• forms-1_001.jpg (GRAPHIC) — 6KB
• forms-1_002.jpg (GRAPHIC) — 74KB
• ex5-1_001.jpg (GRAPHIC) — 33KB
• ex5-1_002.jpg (GRAPHIC) — 32KB
• ex5-1_003.jpg (GRAPHIC) — 14KB
• ex23-2_001.jpg (GRAPHIC) — 159KB
• 0001493152-25-027067.txt ( ) — 1187KB
• ex107_htm.xml (XML) — 17KB

RISK FACTORS

RISK FACTORS 7 THE NOVEMBER 2025 ALUMNI CAPITAL TRANSACTION 10 THE ALUMNI CAPITAL ELOC TRANSACTION 12 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 17 TRADEMARKS, SERVICE MARKS AND TRADE NAMES 18

USE OF PROCEEDS

USE OF PROCEEDS 19 DIVIDEND POLICY 20

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 21 SELLING STOCKHOLDERS 23 PLAN OF DISTRIBUTION 25 LEGAL MATTERS 26 EXPERTS 26 INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE 27 WHERE YOU CAN FIND MORE INFORMATION 28 You should rely only on the information contained in this prospectus or incorporated by reference. Neither we nor the Selling Stockholders have authorized any other person to provide you with information different from or in addition to that contained in this prospectus, and neither we nor the Selling Stockholders take responsibility for any other information others may give you. If anyone provides you with different or inconsistent information, you should not rely on it. The Selling Stockholders are not making an offer to sell these securities in any jurisdiction where an offer or sale is not permitted. Except as otherwise stated, you should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus and that the information in any report incorporated by reference is accurate only as of the date of such report. Our business, financial condition, results of operations and prospects may have changed since such dates. No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectus applicable to that jurisdiction. As used in this prospectus, unless the context indicates or otherwise requires, “the Company,” “our Company,” “we,” “us,” and “our” refer to Azitra, Inc., a Delaware corporation. i INDUSTRY AND MARKET DATA This prospectus contains or incorporates by reference observati

View Full Filing

View this S-1 filing on SEC EDGAR